ON123300

Catalog No.S8161 Batch:S816102

Print

Technical Data

Formula

C24H27N7O
Molecular Weight 429.52 CAS No. 1357470-29-1
Solubility (25°C)* In vitro DMSO 29 mg/mL (67.51 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ON123300 is a potent and multi-targeted kinase inhibitor with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM for CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), and Fyn, respectively.
Targets
CDK4/CyclinD1 [3]
(Cell-free assay)		 RET [1]
(Cell-free assay)		 CDK6/CyclinD1 [3]
(Cell-free assay)		 Fyn [1]
(Cell-free assay)		 PDGFRβ [3]
(Cell-free assay)		 View More
3.87 nM 9.2 nM 9.82 nM 11 nM 26 nM
In vitro

ON123300 inhibits U87 glioma cell proliferation with an IC50 3.4±0.1 μmol/L and reduces phosphorylation of Akt, yet it also unexpectedly induces Erk activation, both in a dose- and time-dependent manner that subsequently is attributed to relieving Akt mediated C-Raf S259 inactivation and activating a p70S6K-initiated PI3K-negative feedback loop[1]. ON123300 also inhibits CDK4/6 and PI3K-δ and exhibits potent activity against mantle cell lymphomas (MCLs). ON123300 is a potent inhibitor of CDK4, with an IC50 of 3.8 nM, with little inhibitory activity against CDKs 1,2,5 and 8. MCL cell lines treated with ON123300 accumulate in the G1 phase at lower concentrations (0.1-1.0μM), at higher concentrations of the compound, a large proportion of the cells progress through the S and G2/M phases of the cell cycle and eventually accumulate in the sub-G1 phase, suggesting an induction of apoptosis. ON123300 also inhibits the phosphorylation of pRb and p130 in a dose-dependent manner. ON123300 treatment results in inhibition of FOXO1 phosphorylation, a target of mTOR[3].
In vivo

In a preclinical brain tumor model (U87MG), ON123300 shows high brain and brain tumor accumulation. Consistent with the in vitro studies, single agent ON123300 causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors[1]. ON123300 is highly bound (99.4%) to plasma proteins in mice and rapidly penetrates into brain. It has proficient BBB penetration and accumulates in normal brain[2]. The pharmacokinetic profiles of plasma ON123300 concentration are multiexponential and overall declines fairly rapidly with terminal elimination half-lives of 1.5 hours[1]. Mouse xenograft assays show a strong inhibition of MCL tumor growth in ON123300-treated animals. Safety studies in mice suggest that ON123300 is orally bio-available and is minimally toxic when administered orally or intraperitoneally[3].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    U87 glioma cells

  • Concentrations

    --

  • Incubation Time

    72 h

  • Method

    The cytotoxicity of ON123300 is determined using a colorimetric sulforhodamine B (SRB)-based assay. Suspensions of glioma cells (100 mL containing 2×103 cells) are seeded in 96-well plates and allowed to attach to the surface by overnight incubation. The cells are then treated with increasing concentrations of ON123300 for 72 hour. At the end of the treatment, cells are fixed with 10% (v/v) trichloroacetic acid (TCA) and stained with 0.4% SRB. The optical densities are measured at a wavelength of 570 nm. 
Animal Study:

[1]
  • Animal Models

    NIH Swiss nude mice

  • Dosages

    5 and 25 mg/kg

  • Administration

    i.v.

Selleck's ON123300 has been cited by 3 publications

NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancer [ Cell Rep, 2024, 43(7):114446] PubMed: 38996065
Activation of salt Inducible Kinases, IRE1 and PERK leads to Sec bodies formation in Drosophila S2 cells [ J Cell Sci, 2021, jcs.258685] PubMed: 34350957
Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors. [ Molecules, 2020, 8;25(9) pii: E2220] PubMed: 32397330

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.